CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Georgette Verdin as the Company’s Chief People Officer.
“Our people are central to achieving our vision of transforming the use of radiopharmaceuticals in oncology. We are invested in and committed to building a culture that values diversity and inclusivity and promotes career development for all. Reflecting this, I am excited that Georgette is joining Curie. Her deep experience in company building, leadership of Human Resources at both small and large companies, as well as experience inside and outside of the biotech sector will ensure that Curie will continue to attract and retain talented people”, said Simon Read, Curie’s CEO and founder.
Ms. Verdin brings 30 years of leading organizational and talent strategy and execution across the biotech and technology sectors, most recently as Chief Human Resources Officer at AVROBIO, and as Global Executive Leader of People & Organization at Novartis Institutes of BioMedical Research. She has also held HR management roles at Biogen Idec., Microsoft Corporation and Amazon. She earned a B.A. in Spanish and history at Georgetown University, an M.A. in international relations from The American University, and management training at the INSEAD School of Management.
“I am thrilled to join the Curie team during this exciting phase of growth,” said Ms. Verdin. “I look forward to implementing an HR strategy that supports the hiring, retention, engagement and management of a team focused on advancing Curie’s mission to bring precision radiopharmaceutical therapies to the many patients who need them.”
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com
